CORE C : Genomics Core (Two components: Affymetrix and Virus ) 1: Affymetrix microarray analysis of gene expression: Several components of this project will require analysis of gene expression in whole or micro-dissected liver tissue, from mouse and human samples. These studies will be performed in the genomics core for research of the department of Pathology. This core utilizes state of the art Affymetrix oligo-based cDNA microarrays (Mouse, human, C.Elegans, etc) for quantitative gene expression analysis. This facility is directed by Dr. Jian-Hua Luo, associate professor, department of pathology. Samples are provided as frozen tissue, on which, the facility performs RNA extraction and all other processing steps and provides the final data/results. This facility routinely processes human, mouse and rat samples and provides bio-informatic supportfor statistical analysis and data interpretation. 2: Virus core: Several components of this project will require genetic interventions readily supplied by Adeno-Associated Virus(AAV), recombinant adenovirus or Lentivirus. The virus core will collaborate with all investigators in this project for the design and preparation of suitable AAV or lentiviral based vectors to deliver transgenes and/or silencing RNA for overexpression or gene knock-down studies. This core will be directed by Dr. Aaron Bell, assistant professor, department of Pathology, who is highly experienced in AAV vector design. These approaches are well established in hepatic biology literature, and is already being used by Drs. Bell and Michalopoulos in collaborative research unrelated to this project which has validated its specificity and effectiveness. The AAV vectors allow for expression of transgenes up to 5KB and easily accommodates siRNA expression cassettes for gene knock-down studies.
a -1-Antitrypsin deficiency is the most common cause of pediatric metabolic liver disease and can lead to cirrhosis and hepatocellular carcinoma in adults. Characterizing altered gene expression patterns and manipulation of gene expression with viral vectors currently used for clinical gene therapy applications is necessary to better understand the disease and may identify therapeutic targets and treatment modalities.
|O'Reilly, Linda P; Long, Olivia S; Cobanoglu, Murat C et al. (2014) A genome-wide RNAi screen identifies potential drug targets in a C. elegans model of ?1-antitrypsin deficiency. Hum Mol Genet 23:5123-32|
|Long, Olivia S; Benson, Joshua A; Kwak, Joon Hyeok et al. (2014) A C. elegans model of human ?1-antitrypsin deficiency links components of the RNAi pathway to misfolded protein turnover. Hum Mol Genet 23:5109-22|
|Miedel, Mark T; Zeng, Xuemei; Yates, Nathan A et al. (2014) Isolation of serpin-interacting proteins in C. elegans using protein affinity purification. Methods 68:536-41|
|Bhatia, Sangeeta N; Underhill, Gregory H; Zaret, Kenneth S et al. (2014) Cell and tissue engineering for liver disease. Sci Transl Med 6:245sr2|
|O'Reilly, Linda P; Luke, Cliff J; Perlmutter, David H et al. (2014) C. elegans in high-throughput drug discovery. Adv Drug Deliv Rev 69-70:247-53|
|Chu, Andrew S; Perlmutter, David H; Wang, Yan (2014) Capitalizing on the autophagic response for treatment of liver disease caused by alpha-1-antitrypsin deficiency and other genetic diseases. Biomed Res Int 2014:459823|
|O'Reilly, Linda P; Perlmutter, David H; Silverman, Gary A et al. (2014) *1-antitrypsin deficiency and the hepatocytes - an elegans solution to drug discovery. Int J Biochem Cell Biol 47:109-12|
|Li, Jie; Pak, Stephen C; O'Reilly, Linda P et al. (2014) Fluphenazine reduces proteotoxicity in C. elegans and mammalian models of alpha-1-antitrypsin deficiency. PLoS One 9:e87260|
|Fox, Ira J; Daley, George Q; Goldman, Steven A et al. (2014) Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease. Science 345:1247391|
|Wang, Yan; Perlmutter, David H (2014) Targeting intracellular degradation pathways for treatment of liver disease caused by *1-antitrypsin deficiency. Pediatr Res 75:133-9|
Showing the most recent 10 out of 14 publications